Drug Store News - SKB, SkyePharma ink pact for once-daily Requip
SmithKline Beecham and SkyePharma have entered into a development and licensing agreement for a once-daily version of SKB’s anti-Parkinson’s disease drug, Requip (ropinirole), using SkyePharma’s Geomatrix oral delivery technology. The new formulation is expected to provide a simplified regimen for patients on Requip therapy.
Related Results
Requip for RLSRequip reduces risk of dyskinesiasRequip now has generic competitorsGSK’s Requip significantly improves restless legs syndromeRequip shows use for restless legs syndrome.
Under the terms of the agreement, SkyePharma will be responsible for all development activities for Requip oral controlled-release tablets, up to regulatory filing, in collaboration with SKB. Requip is indicated for the treatment of Parkinson’s disease, both as initial monotherapy in early stage patients and as adjunctive therapy with L-dopa to control motor fluctuations. Launched in 1997 in the U.S., Requip is currently administered three times daily.
COPYRIGHT 1999 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2008 Gale, Cengage Learning
